Skip to content
  • Print

Kate M. O'Dell, PharmD, BCPS



Phone: 209.946.7462


PharmD, University of Michigan, 1999

PostDoc, Pharmaceutical Outcomes Research Fellowship, Henry Ford Hospital, Detroit, Michigan

At Pacific Since: 2004

Kate M. O'Dell, PharmD, BCPS earned her doctor of pharmacy from University of Michigan, Ann Arbor. She also completed a fellowship in pharmaceutical outcomes research at Henry Ford Health-Systems in Detroit, Mich. In addition she is a Board Certified Pharmacotherapy Specialist. She is a member of the California Society of Health-System Pharmacists, the American College of Clinical Pharmacy and the Board of Pharmaceutical Specialties.

Dr. O'Dell joined the Pacific Pharmacy Family in 2004. In addition to her role as a Professor, she is the Director of Professional Programs and Vice Chair of Pharmacy Practice. She has a wealth of experience in experiential pharmacy education. She has worked as a regional coordinator for the past 10 years and she prides herself on her ability to support students as they apply classroom knowledge to practical settings.

As the director of experiential programs, Dr. O'Dell is tasked with supporting the integration of the Introductory Pharmacy Practice Experience (IPPE) and Advanced Pharmacy Practice Experience (APPE) Programs. She partners with experiential coordinators and staff in an endeavor to streamline operational functions of these programs. It is her goal to continue to work with the large cohort of preceptors and decision makers to enhance experiential education. Prior to her current role she served as a regional coordinator at Travis Air Force Base.

She appreciates that at Pacific there is an emphasis on student-focused teaching and learning. She is impressed by the high caliber of the student leadership and organizations. Dr. O'Dell makes it a priority to mentor students so that they can achieve the highest level of academic success and be prepared to embark on their profession as practicing pharmacists. She thinks highly of the sense of collaboration and camaraderie among her peers at Pacific.

Born into an immigrant family, Dr. O'Dell is the youngest of four siblings. She carries with her the spirit of her parents who developed her work ethic, humility and respect. In her free time Dr. O'Dell enjoys expanding her mind by studying music theory and playing the piano with her son, who is also a musician.


Teaching Philosophy: “Pharmacy practice experiential education allows the students to use their learned skills to apply and practice in various healthcare settings. Students should be self-motivators, critical thinkers, problem solvers and lifelong learners. I expect my students to demonstrate exceptional professionalism and ethical conduct. As your faculty, I will take a great interest in mentoring you to achieve success, but I should only be the second person to have such great interest. Can you guess who the first is?”


  • PHRM 149 - Hospital Introductory Pharmacy Practice Experience
  • PHRM 172 - Ambulatory Care Advanced Pharmacy Practice Experience

Research Interests:

  • Pharmaceutical Outcomes
  • Anticoagulation
  • Cardiology
  • Ambulatory Care Services

Boyce EG, Vyas D, Rogan EL, Valle-Oseguera CS, O'Dell KM. Impact of tofacitinib on patient outcomes in rheumatoid arthritis - review of clinical studies. Patient Related Outcome Measures 2016; 7:1-12.

Vyas D, O'Dell KM, Bandy JL, Boyce EG. Tofacitinib: The First Janus Kinase (JAK) Inhibitor for the Treatment of Rheumatoid Arthritis. Annals of Pharmacotherapy 2013; 47(11):1524-31.

O'Dell KM, Rummel AE.  Tofacitinib: a Janus kinase inhibitor for the treatment of rheumatoid arthritis. Formulary. 2012; 47:350-8.

O'Dell KM, Shah SA.  Evaluation of pharmacy practice residents' research abstracts and publication rate. JAPhA. 2012; 52(4):524-7.

O'Dell KM, Igawa D, Hsin J. The new oral anticoagulants for atrial fibrillation: a review of clinical trials. Clin Ther. 2012; 34:894-901.

O'Dell KM, Rummel AE, Fang NC, Nguyen NN.  Linaclotide: a guanylate cyclase type-C agonist for the treatment of constipation-predominant irritable bowel syndrome and chronic constipation. Formulary. 2012; 47:15-22.

Draskovich C, O'Dell KM.  Dronedarone for atrial fibrillation: An update of clinical evidence. Formulary. 2010; 45:276-283.